Ciphergen Stock Slides 8.3 Percent on Revenue Investigation, Delayed Q3 Earnings | GenomeWeb

NEW YORK, Nov. 7 (GenomeWeb News) - Shares in Ciphergen Biosystems were down 8.3 percent, or $.16, at $1.77 in mid-afternoon trading after the company said an audit committee has begun investigating $500,000 in sales recorded in the second quarter.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.